Skip to main content
OpenTrials
Completed

NCT Number: NCT06877039

Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever

The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dengue Fever Arbovirus Infections Dengue Flaviviridae Infections Flavivirus Infections Hemorrhagic Fevers, Viral Infections Mosquito-Borne Diseases RNA Virus Infections Vector Borne Diseases Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, 528051, Guangdong, China.

Foshan, Guangdong, 528000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Inclusion Criteria**:
  • Meet the clinical diagnostic criteria for dengue fever, with blood indicators showing that the dengue antigen is positive.
  • No age limit for inclusion.
  • Voluntarily agree to participate in the study and sign the informed consent.
  • Complete clinical data available, including symptoms and laboratory tests, to support subsequent analysis.
  • Exclusion Criteria**:
  • Incomplete or unavailable clinical data. Patients will be excluded if sufficient laboratory data and symptoms cannot be collected.
  • Unable to understand or unwilling to sign the informed consent for any reason.

Treatment and study plan

Observational studies did not involve any interventions

Other

Primary outcomes

  1. WBC

    Time frame: From January 2024 to December 2024

    WBC (White Blood Cell count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

  2. HGB (Hemoglobin)

    Time frame: From January 2024 to December 2024

    HGB (Hemoglobin), unit: g/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

  3. PLT (Platelet count)

    Time frame: From January 2024 to December 2024

    PLT (Platelet count), unit: cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

  4. ANC (Absolute Neutrophil Count)

    Time frame: From January 2024 to December 2024

    ANC (Absolute Neutrophil Count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

Sponsors and collaborators

Lead sponsor

Foshan Hospital of Traditional Chinese Medicine

Other

Registry information

Official study title

Observational Study on the Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 14, 2025
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.